Search the Newsreel

Pulse Biosciences Inc (PLSE) Institutional Confidence

Pulse Biosciences Inc (PLSE) has an institutional shareholding score of 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. Institutional shareholding proportion increased by 30.37% quarter-over-quarter, reaching 11.76%. The largest institutional shareholder, Bill Nygren | OAKMX, holds 6.89K shares, …

Pulse Biosciences' Atrial-Fibrillation Study Passes Halfway Mark

Pulse Seismic Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Pulse Seismic Inc. Reports Q2 2026 Financial Results and Declares Regular Quarterly Dividend

CALGARY, Alberta, July 28, 2026 (GLOBE NEWSWIRE) -- Pulse Seismic Inc. (TSX:PSD) (OTCQX:PLSDF) (“Pulse” or the “Company”) is pleased to report its financial and operating results for the three and six months ended June 30, 2026. The unaudited condensed consolidated interim financial statements, accompanying …

Pulsar Group PLC Revenue Breakdown – LSE:PULS

$Pulse Biosciences (PLSE.US)$ the squeeze is onnnnnnnnn

The article is a short social media post by user Papacito on the moomoo Community platform, stating that Pulse Biosciences ($PLSE.US$) is "squeeeeezing." The post consists of a single sentence and a featured image, focusing on the potential for a short squeeze in the …

Oppenheimer raises Pulse Biosciences stock price target on AF data

Oppenheimer has increased its price target for Pulse Biosciences (NASDAQ:PLSE) to $35.00 from $30.00, maintaining an Outperform rating, following positive data from the company's nsPFA EFS study on atrial fibrillation. The stock has seen a 142% surge in the past six months and is …

Pulse Biosciences (PLSE) Stock Looks Above Fair Value Today

Pulse Biosciences Inc (PLSE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Pulse Biosciences Inc (PLSE), categorizing its revenue by business segments (Systems, Cycle units) and geographical regions (North America, Rest of World). The data presented shows that as of the updated information on Tuesday, January 6, the …

Pulsenmore Ord Shs (PLSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Pulsenmore Ord Shs (PLSM), covering various indicators such as MACD, RSI, and moving averages. It summarizes the current signals from these indicators, noting an overall neutral signal based on today's moving averages and other technical indicators. The …

Pulse Biosciences Inc (PLSE) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulse Biosciences Inc (PLSE) dividend history and stock split events. It indicates that the company has not distributed any dividends over the past five years. The page lists current stock pricing and market capitalization information for PLSE.

Pulse Biosciences Inc (PLSE) Cash Flow

This article provides a detailed historical overview of Pulse Biosciences Inc's (PLSE) cash flow statements, including operating, investing, and financing activities, presented quarterly and annually. It highlights key financial figures such as operating cash flow, net income from continuing operations, capital expenditures, and free …

PLSM|Pulsenmore Ord Shs|Price:3.430|Chg%:-0.230

Pulsenmore Ltd is an Israel-based medical equipment company focused on developing portable ultrasound devices for home use, particularly for pregnant women (PulseNmore ES) and women undergoing in vitro fertilization (PulseNmore FC). These systems allow remote physical examination and monitoring via telehealth technology, utilizing smartphones …

Pulsenmore Ltd. Revenue Breakdown – NASDAQ:PLSM

This article provides a revenue breakdown for Pulsenmore Ltd. (NASDAQ: PLSM), highlighting that the largest contribution to its revenue came from Israel, generating $2.85 million USD last year, compared to $2.49 million USD the previous year. The data is presented from TradingView, focusing on …

UL Solutions Inc. $ULS Shares Sold by Walleye Capital LLC

Gulshan Polyols confirms no UPSI shared in NDTV media interaction

UL Solutions Inc. Revenue Breakdown – NYSE:ULS

Why Pulse Seismic Inc stock is sliding today

Pulse Biosciences stock hits 52-week high at 31.09 USD

Pulse Biosciences Inc. reached a new 52-week high of $31.09, driven by significant stock appreciation, positive Q1 2026 financial results where EPS beat expectations, and strategic moves like warrant redemptions. The company also received a "buy" rating and $32 price target from Canaccord Genuity, …

Pulse Biosciences (NASDAQ:PLSE) Reaches New 12-Month High - Still a Buy?

Pulse Biosciences to report Q2 2026 results on August 6

Pulse Biosciences, Inc. announced it will release its Q2 2026 financial results after market close on August 6, 2026, followed by a conference call at 1:30 PM PT to discuss business updates. The company utilizes its Nanosecond Pulsed Field Ablation (nsPFA) technology and will …

UL Solutions Sets Date for Second Quarter Results

NORTHBROOK, Ill., July 21, 2026--(BUSINESS WIRE)--UL Solutions Inc. (NYSE: ULS), a global leader in applied safety science, today announced it will release financial results for the second quarter before the market opens on Tuesday, Aug. 4. Management will host a webcast and conference call …

Pulse Biosciences, Inc (PLSE) Stock Analysis: Unpacking The 5.89% Potential Upside

Pulse Biosciences, Inc (PLSE) is a U.S.-based medical instruments and supplies company with a $2 billion market capitalization, specializing in bioelectric medicine through its nPulse System. Despite analysts forecasting a potential 5.89% upside with a target price between $30.00 and $32.00, the company faces …

Pulse Biosciences schedules its next financial update for Aug. 6

Gulshan Polyols receives ₹5 Cr incentive under NEIDS from DPIIT

Pulsenmore (PLSM) completes $7.5M exempt warrant offering

Pulsenmore Ltd. (PLSM), an Israeli health care biotechnology company, has completed an exempt securities offering under Rule 506(b) of Regulation D, raising $7.5 million. The offering involved the sale of 1,562,500 pre-funded warrants and 1,562,500 ordinary warrants at $4.7999 each. The company plans to …

Pulsenmore Expands Home Ultrasound Clinical Utility, Backed by New Clinical Evidence

Pulsenmore has expanded the clinical utility of its home ultrasound platform with new evidence supporting advanced prenatal assessments. Two independent peer-reviewed studies published in the International Journal of Gynecology & Obstetrics and AJOG MFM demonstrated the successful use of Pulsenmore's platform for remote Biophysical …

PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

Pulse Biosciences announced inducement grants to three new employees consistent with Nasdaq Listing Rule 5635(c)(4). These grants, totaling 51,000 stock options and 21,000 restricted stock units, were approved by the Compensation Committee and are intended to align the interests of new hires with those …

Pulse Biosciences' Three New Employees Get $25.89 Options

REG - Pulsar Helium Inc. - Results of Fundraise and TVR

REG - Pulsar Helium Inc. - Pulsar Helium - Retail Offer

UL Solutions’ 10.1M-share rebound restores attention, but the signal is still balanced near the upper range

ULS rose 8.4% in the latest week on 2.5x its 13-week average volume, yet the four-week return remains slightly negative and activity pressure has cooled from May levels.

PLSE Forecast — Price Target — Prediction for 2027

Price to earnings forward of Pulsar Helium, Inc. – TSXV:PLSR

Pulsar Files Financial and Operating Results for the Second Quarter Ended March 31, 2026

Pulsar Helium boosted as Minnesota rule change gives clarity to route ahead for Topaz project